Understanding Vascular Toxicity of Indigo Naturalis in Anti-Inflammatory Applications: Mendelian Randomization and Co-localization Study

Abstract

Background: Indigo naturalis (IN), a traditional Chinese herbal medicine, shows promising potential for treating autoimmune inflammatory diseases. However, its clinical translation and application are being limited by concerns regarding vascular toxicity.

Methods: Mendelian randomization (MR) and colocalization analyses were conducted to systematically investigate the target-specific vascular risks associated with IN.

Results: Causal associations were identified between four targets of IN and multiple vascular disorders, including deep vein thrombosis (DVT) (OR = 1.001, 95% CI = 1.003–1.000, P = 0.008), among others. Notably, urate was identified as a mediator between IN and DVT, exhibiting a mild mediation effect (7.3%, P = 0.048).

Conclusion: For the first time, the causal effects of IN on vascular toxicity were demonstrated using MR. This study provides insights into the safety implications of IN for anti-inflammatory applications, which would facilitate evidence-based research on IN and its clinical translation.

Keywords

Indigo naturalis / Mendelian randomization / urate / vascular toxicity

References

[1] Xu Y, Lin C, Tan H, Bian Z. The double-edged sword effect of indigo naturalis. Food Chem Toxicol 2024; 185: 114476. [PMID: 38301993 DOI: 10.1016/j.fct.2024.114476]

[2] Sugimoto S, Naganuma M, Kiyohara H, Arai M, Ono K, et al. Clinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study. Digestion 2016; 93(3): 193-201. [PMID: 26959688 DOI: 10.1159/000444217]

[3] Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, et al. Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis. Gastroenterology 2018; 154(4): 935-47. [PMID: 29174928 DOI: 10.1053/j.gastro.2017.11.024]

[4] Matsuno Y, Torisu T, Umeno J, Shibata H, Hirano A, et al. One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study. Intest Res 2022; 20(2): 260-8. [PMID: 35508956 DOI: 10.5217/ir.2021.00124]

[5] Ben-Horin S, Kopylov U, Salomon N. Curcumin-QingDai combination as treatment for moderate-severe ulcerative colitis. Case Rep Gastroenterol 2022; 16(3): 563-8. [PMID: 36824698 DOI: 10.1159/000526646]

[6] Ozawa K, Mori D, Hatanaka A, Sawano T, Nakatani J, et al. Comparison of the anti-colitis activities of Qing Dai/Indigo Naturalis constituents in mice. J Pharmacol Sci 2020; 142(4): 148-56. [PMID: 32033881 DOI: 10.1016/j.jphs.2020.01.003]

[7] Naganuma M, Sugimoto S, Suzuki H, Matsuno Y, Araki T, et al. Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. J Gastroenterol 2019; 54(10): 891-6. [PMID: 31102012 DOI: 10.1007/s00535-019-01591-9]

[8] Masaki T, Okazawa M, Asano R, Inagaki T, Ishibashi T, et al. Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci USA 2021; 118(11): e2023899118. [PMID: 33836606 DOI: 10.1073/pnas.2023899118]

[9] Kazi JU, Rönnstrand L. FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications. Physiol Rev 2019; 99(3): 1433-66. [PMID: 31066629 DOI: 10.1152/physrev.00029.2018]

[10] Wilson KR, Villadangos JA, Mintern JD. Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy. Immunol Cell Biol 2021; 99(9): 962-71. [PMID: 34097779 DOI: 10.1111/imcb.12484]

[11] Hoessel R, Leclerc S, Endicott JA, Nobel MEM, Lawrie A, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1(1): 60-7. [PMID: 10559866 DOI: 10.1038/9035]

[12] Adachi J, Mori Y, Matsui S, Takigami H, Fujino J, et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chemy 2001; 276(34): 31475-8. [PMID: 11425848 DOI: 10.1074/jbc.c100238200]

[13] Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001; 276(1): 251-60. [PMID: 11013232 DOI: 10.1074/jbc.M002466200]

[14] Sugihara K, Kitamura S, Yamada T, Okayama T, Ohta S, et al. Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo. Biochem Biophys Res Commun 2004; 318(2): 571-8. [PMID: 15120638 DOI: 10.1016/j.bbrc.2004.04.066]

[15] Xu Y, Shi J, Mok HL, Lyu C, Chen J, et al. Macrophage-mediated transport of insoluble indirubin induces hepatic injury during intestinal inflammation. Adv Sci (Weinh) 2025; 12(36): e02993. [PMID: 40546113 DOI: 10.1002/advs.202502993]

[16] Kwapiszewska G, Johansen AKZ, Gomez-Arroyo J, Voelkel NF. Role of the aryl hydrocarbon receptor/ARNT/cytochrome P450 system in pulmonary vascular diseases. Circ Res 2019; 125(3): 356-66. [PMID: 31242807 DOI: 10.1161/circresaha.119.315054]

[17] Wang H, Wang Z, Wei C, Wang J, Xu Y, et al. Anticancer potential of indirubins in medicinal chemistry: biological activity, structural modification, and structure-activity relationship. Eur J Med Chem 2021; 223: 113652. [PMID: 34161865 DOI: 10.1016/j.ejmech.2021.113652]

[18] Gaboriaud-Kolar N, Vougogiannopoulou K, Skaltsounis AL. Indirubin derivatives: a patent review (2010 - present). Expert Opin Ther Pat 2015; 25(5): 583-93. [PMID: 25887337 DOI: 10.1517/13543776.2015.1019865]

[19] Humphrey JD, Schwartz MA. Vascular mechanobiology: homeostasis, adaptation, and disease. Annu Rev Biomed Eng 2021; 23(1): 1-27. [PMID: 34255994 DOI: 10.1146/annurev-bioeng-092419-060810]

[20] Balta S. Endothelial dysfunction and inflammatory markers of vascular disease. Curr Vasc Pharmacol 2021; 19(3): 243-9. [PMID: 32316894 DOI: 10.2174/1570161118666200421142542]

[21] Bakker MK, van Straten T, Chong M, Paré G, Gill D, et al. Anti-epileptic drug target perturbation and intracranial aneurysm risk: mendelian randomization and colocalization study. Stroke 2023; 54(1): 208-16. [PMID: 36300369 DOI: 10.1161/strokeaha.122.040598]

[22] Yang Y, Chen B, Zheng C, Zeng H, Zhou J, et al. Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization study. Cell Biosci 2024; 14(1): 36. [PMID: 38504335 DOI: 10.1186/s13578-024-01214-8]

[23] Iturrieta-Zuazo I, Walter S . Mendelian randomization: present and future of epidemiological studies in cardiology. Rev Esp Cardiol 2015; 68(2): 87-91. [PMID: 25449812 DOI: 10.1016/j.rec.2014.06.024]

[24] Deng Z, Long W, Duan H, Hui X, Tao T. Diabetes mellitus and pancreatic cancer: investigation of causal pathways through mendelian randomization analysis. BIOI 2023; 4(4): 160-69. [DOI: 10.15212/bioi-2023-0014]

[25] Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, et al. The MR-base platform supports systematic causal inference across the human phenome. ELife 2018; 7: e34408. [PMID: 29846171 DOI: 10.7554/elife.34408]

[26] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 1995; 57(1): 289-300. [DOI: 10.1111/j.2517-6161.1995.tb02031.x]

[27] Hong S, Chen L, Zhou X, Huang Y, Tian Y, et al. Genetically predicted causal effects of gut microbiota on spinal pain: a two-sample Mendelian randomization analysis. Front Microbiol 2024; 15: 1357303. [PMID: 38591041 DOI: 10.3389/fmicb.2024.1357303]

[28] Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet 2021; 53(2): 156-65. [PMID: 33462485 DOI: 10.1038/s41588-020-00763-1]

[29] Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 2014; 10(5): e1004383. [PMID: 24830394 DOI: 10.1371/journal.pgen.1004383]

[30] Weng H, Li H, Zhang Z, Zhang Y, Xi L, et al. Association between uric acid and risk of venous thromboembolism in East Asian populations: a cohort and Mendelian randomization study. Lancet Reg Health West Pac 2023; 39: 100848. [PMID: 37565068 DOI: 10.1016/j.lanwpc.2023.100848]

[31] Yen F, Hsu C, Li H, Wei JC, Hwu C. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. PLoS One 2020; 15(6): e0234909. [PMID: 32574194 DOI: 10.1371/journal.pone.0234909]

[32] Gasiewicz TA, Singh KP, Casado FL. Aryl hydrocarbon receptor and stem cells. Stem Cells Int 2017; 2017: 4602854. [PMID: 28163722 DOI: 10.1155/2017/4602854]

[33] del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, et al. Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis 2012; 33(1): 205-15. [PMID: 22936007 DOI: 10.3233/jad-2012-120805]

[34] Pluta AJ, Studniarek C, Murphy S, Norbury CJ. Cyclin-dependent kinases: masters of the eukaryotic universe. Wiley Interdiscip Rev RNA 2023; 15(1): e1816. [PMID: 37718413 DOI: 10.1002/wrna.1816]

[35] Gu S, Xue Y, Liu X, Tang Y, Wang D, et al. Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway. J Inflamm 2024; 21(1): 44. [PMID: 39501249 DOI: 10.1186/s12950-024-00413-x]

[36] Yuan J, Sun X, Che S, Zhang L, Ruan Z, et al. AhR-mediated CYP1A1 and ROS overexpression are involved in hepatotoxicity of decabromodiphenyl ether (BDE-209). Toxicol Lett 2021; 352: 26-33. [PMID: 34571075 DOI: 10.1016/j.toxlet.2021.09.008]

[37] Huai W, Zhao R, Song H, Zhao J, Zhang L, et al. Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription. Nat Commun 2014; 5(1): 4738. [PMID: 25141024 DOI: 10.1038/ncomms5738]

[38] Ye X, Li H, Anjum K, Zhong X, Miao S, et al. Dual role of indoles derived from intestinal microbiota on human health. Front Immunol 2022; 13: 903526. [PMID: 35784338 DOI: 10.3389/fimmu.2022.903526]

[39] Paul R, Blackburn RS, Bechtold T . Indigo and indigo colorants. In: Ullmann’s encyclopedia of industrial chemistry. Wiley-VCH Verlag GmbH & Co., KGaA; 2021. [DOI: 10.1002/14356007.a14_149.pub3]

[40] Schiering C, Wincent E, Metidji A, Iseppon A, Li Y, et al. Feedback control of AHR signalling regulates intestinal immunity. Nature 2017; 542(7640): 242-5. [DOI: 10.1038/nature21080]

[41] Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Sci Transl Med 2019; 11(508): eaaw8828. [PMID: 31484791 DOI: 10.1126/scitranslmed.aaw8828]

[42] Gebru MT, Atkinson JM, Young MM, Zhang L, Tang Z, et al. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. Blood 2020; 136(9): 1067-79. [PMID: 32396937 DOI: 10.1182/blood.2019003124]

[43] Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol 2020; 13(1): 155. [PMID: 33213500 DOI: 10.1186/s13045-020-00992-1]

[44] Weiss AM, Lopez MA 2nd, Rosenberger MG, Kim JY, Shen J, et al. Identification of CDK4/6 inhibitors as small molecule NLRP3 inflammasome activators that facilitate IL-1β secretion and T cell adjuvanticity. J Med Chem 2024; 67(17): 14974-85. [PMID: 39162654 DOI: 10.1021/acs.jmedchem.4c00516]

[45] Ju Z, Sun J, Liu Y. Molecular structures and spectral properties of natural indigo and indirubin: experimental and DFT studies. Molecules 2019; 24(21): 3831. [DOI: 10.3390/molecules24213831]

[46] Qi-Yue Y, Ting Z, Ya-Nan H, Sheng-Jie H, Xuan D, et al. From natural dye to herbal medicine: a systematic review of chemical constituents, pharmacological effects and clinical applications of indigo naturalis. Chin Med 2020; 15(1): 127. [PMID: 33317592 DOI: 10.1186/s13020-020-00406-x]

[47] Jäger E, Murthy S, Schmidt C, Hahn M, Strobel S, et al. Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. Nat Commun 2020; 11(1): 4243. [PMID: 32843625 DOI: 10.1038/s41467-020-17749-6]

[48] Peng T, Jou M. Oxidative stress caused by mitochondrial calcium overload. Ann N Y Acad Sci 2010; 1201(1): 183-8. [PMID: 20649555 DOI: 10.1111/j.1749-6632.2010.05634.x]

[49] Wu X, Wang S, Lu J, Jing Y, Li M, et al. Seeing the unseen of Chinese herbal medicine processing (Paozhi): advances in new perspectives. Chin Med 2018; 13(1): 4. [PMID: 29375653 DOI: 10.1186/s13020-018-0163-3]

[50] Wu H, Hu T, Hao H, Hill MA, Xu C, et al. Inflammatory bowel disease and cardiovascular diseases: a concise review. Eur Heart J Open 2021; 2(1): oeab029. [PMID: 35919661 DOI: 10.1093/ehjopen/oeab029]

[51] Chen B, Collen LV, Mowat C, Isaacs KL, Singh S, et al. Inflammatory bowel disease and cardiovascular diseases. Am J Med 2022; 135(12): 1453-60. [PMID: 36058305 DOI: 10.1016/j.amjmed.2022.08.012]

[52] Singh S, Kullo IJ, Pardi DS, Loftus EV. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol 2014; 12(1): 26-35. [PMID: 25446727 DOI: 10.1038/nrgastro.2014.202]

[53] Sharma N, Tewatia P, Harvey PR, Kumar A. Controversies in venous thromboembolism risk assessment in inflammatory bowel disease: a narrative review. Diagnostics 2024; 14(19): 2112. [PMID: 39410515 DOI: 10.3390/diagnostics14192112]

[54] Orihara Y, Asakura M, Hida N, Kawai M, Sato T, et al. Effect of oral Qing-Dai medication on pulmonary arterial pressure levels in patients with ulcerative colitis. Circ J 2020; 84(8): 1339-45. [PMID: 32595175 DOI: 10.1253/circj.cj-19-1112]

[55] Wen S, Arakawa H, Tamai I. Uric acid in health and disease: from physiological functions to pathogenic mechanisms. Pharmacol Thers 2024; 256: 108615. [PMID: 38382882 DOI: 10.1016/j.pharmthera.2024.108615]